Ruxolitinib prevents STAT3-phosphorylation (Figure 2D) while increasing IRAK4/NFκB/p38-signaling in CLL cells in vitro (Figures 2B and 3B) and in vivo (Figure 1) (13). Here, IRAK4 is linked to B-cell chronic lymphocytic leukemia.